V

VistaGen Therapeutics Inc
NASDAQ:VTGN

Watchlist Manager
VistaGen Therapeutics Inc
NASDAQ:VTGN
Watchlist
Price: 4.25 USD 7.59% Market Closed
Market Cap: 167.9m USD

Wall Street
Price Targets

VTGN Price Targets Summary
VistaGen Therapeutics Inc

Wall Street analysts forecast VTGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VTGN is 14.79 USD with a low forecast of 12.12 USD and a high forecast of 19.95 USD.

Lowest
Price Target
12.12 USD
185% Upside
Average
Price Target
14.79 USD
248% Upside
Highest
Price Target
19.95 USD
369% Upside
VistaGen Therapeutics Inc Competitors:
Price Targets
LTRN
Lantern Pharma Inc.
467% Upside
PRQR
ProQR Therapeutics NV
321% Upside
251120
Bio-FD&C Co Ltd
22% Upside
SPRB
Spruce Biosciences Inc
156% Upside
KURA
Kura Oncology Inc
229% Upside
086900
Medy Tox Inc
10% Upside
DVAX
Dynavax Technologies Corp
96% Upside
PHIL
Philogen SpA
14% Upside

Revenue
Forecast

Revenue Estimate
VistaGen Therapeutics Inc

For the last 13 years the compound annual growth rate for VistaGen Therapeutics Inc's revenue is -8%. The projected CAGR for the next 3 years is 424%.

-8%
Past Growth
424%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
VistaGen Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Net Income
Forecast

Net Income Estimate
VistaGen Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-90%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is VTGN's stock price target?
Price Target
14.79 USD

According to Wall Street analysts, the average 1-year price target for VTGN is 14.79 USD with a low forecast of 12.12 USD and a high forecast of 19.95 USD.

What is VistaGen Therapeutics Inc's Revenue forecast?
Projected CAGR
424%

For the last 13 years the compound annual growth rate for VistaGen Therapeutics Inc's revenue is -8%. The projected CAGR for the next 3 years is 424%.

Back to Top